SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.06.24 Share Price

Warrant

DE000SU7GBW7

Real-time Boerse Frankfurt Warrants 16:41:13 23/05/2024 BST
0.017 EUR +70.00% Intraday chart for SG/CALL/REGENERON PHARMACEUTICALS/1150/0.01/21.06.24
Current month-44.44%
1 month-72.22%
Date Price Change
23/05/24 0.017 +70.00%
22/05/24 0.01 -50.00%
21/05/24 0.02 +5.26%
20/05/24 0.019 +26.67%
17/05/24 0.015 +87.50%

Real-time Boerse Frankfurt Warrants

Last update May 23, 2024 at 04:41 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SU7GBW
ISINDE000SU7GBW7
Date issued 25/01/2024
Strike 1,150 $
Maturity 21/06/2024 (29 Days)
Parity 100 : 1
Emission price 0.14
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 0.16
Lowest since issue 0.001
Delta0.06x
Omega 26.07
Premium16.44x
Gearing415.58x
Moneyness 0.8606
Difference Strike 160.3 $
Difference Strike %+13.94%
Spread 0.01
Spread %37.04%
Theoretical value 0.0220
Implied Volatility 32.57 %
Total Loss Probability 94.80 %
Intrinsic value 0.000000
Present value 0.0220
Break even 1,152.38 €
Theta-0.01x
Vega0x
Rho0x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
983.8 USD
Average target price
1,042 USD
Spread / Average Target
+5.91%
Consensus